Biophytis Launches Joint Venture Operations in China

Biophytis SA has announced the operational launch of its joint venture in China, marked by the creation of Biophytis Biopharmaceutical Shenzhen. This subsidiary is situated within a business incubator at Shenzhen Polytechnic University. A dedicated team has been established to initiate the SARA-31 Phase 3 study on sarcopenia. Coordination with Biophytis' Parisian team is crucial for the study's regulatory dossier preparation and submission to Chinese authorities.

The venture is part of a broader effort with Asian partners to accelerate BIO101's development. The next steps involve submitting a pre-IND dossier to the National Medical Products Administration and finalizing legal documents for the Hong Kong joint venture. Initial financing of $3 million is expected, as part of a $20 million commitment over three years.